Reducing Treatment Cost, Provider Liability & Patient Morbidity
through patented devices enabling direct antibiotic delivery
Periprosthetic Joint Infection (PJI) is devastating to patient health, frustrating to surgeons, and costly to our healthcare system. This is a lifetime risk for patients who have received a replacement joint (Knee, Hip, Shoulder). It occurs as acute (post-operative), chronic or hematogenous (blood borne). By 2024, PJI will represent a total US economic burden of $3.9B/yr with 141,000 PJI cases/yr projected.
Physicians are using proven antibiotics, however due to challenging anatomy and protective bacterial biofilm, current treatment options fall short with:
- Failure Rates averaging 10-50% across options
- Treatment Cost: $49k-163k per patient
- Patient Recovery: 2-12mos with risk of repeated surgery
ForCast Orthopedics, ADK (Antibiotic Dispensing Knee) Spacer, RIDDS (Remote Implantable Drug Delivery System) have not yet been reviewed or cleared for use in the United States by the Food and Drug Administration. It is currently not available for sale. This site is a solicitation for investment and corporate relationships